6634 Share Price Performance
NT$63.50
12.50 (24.51%)
Price NT$63.50
Share Pricen/a
Sinew Pharma Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6634 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Sinew Pharma Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.74
- 78.72%
- -263,287.23%
- 0%
About 6634
- Founded
- 2014
- Employees
- 57
- CEO
- WebsiteView website
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
